US Pharma MarketingAlzheon outlines plans for major fundraising round despite Phase 3 miss for Alzheimer
Alzheon, a biotech that has been attempting to treat Alzheimer Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's…
Alzheon, a biotech that has been attempting to treat Alzheimer's with a checkered drug candidate for more than a decade, is plotting a major fundraise.
The Framingham, MA-based biotech outlined an up to $500 million ...
Source: Endpoints News